Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer in adults. Prevision Medicine, a Swiss-based company and leader in functional precision medicine, announced the clinical launch of its cutting-edge Glioblastoma Drug-Screening Test for research use only, powered by the company’s proprietary PrevisionOne platform. The test is designed to help oncologists rapidly identify the most effective therapies for patients affected by GBM.

This milestone comes just a few weeks after the company’s successful launch of its breakthrough drug screening test for Acute Myeloid Leukemia (AML), underscoring its ongoing progress in expanding precision oncology solutions.